From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Current Topics in Microbiology and Immunology
Springer, Berlin, Heidelberg  2017
Accelerating Vaccine Development During the 2013–2016 West African Ebola Virus Disease Outbreak
Elizabeth S. Higgs, Sheri A. Dubey, Beth A. G. Coller, Jakub K. Simon, Laura Bollinger, Robert A. Sorenson, Barthalomew Wilson, Martha C. Nason, Lisa E. Hensley
First Online: 17 September 2017
Abstract
The Ebola virus disease outbreak that began in Western Africa in December 2013 was unprecedented in both scope and spread, and the global response was slower and less coherent than was optimal given the scale and pace of the epidemic. Past experience with limited localized outbreaks, lack of licensed medical countermeasures, reluctance by first responders to direct scarce resources to clinical research, community resistance to outside interventions, and lack of local infrastructure were among the factors delaying clinical research during the outbreak. Despite these hurdles, the global health community succeeded in accelerating Ebola virus vaccine development, in a 5-month interval initiating phase I trials in humans in September 2014 and initiating phase II/III trails in February 2015. Each of the three Ebola virus disease-affected countries, Sierra Leone, Guinea, and Liberia, conducted a phase II/III Ebola virus vaccine trial. Only one of these trials evaluating recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein demonstrated vaccine efficacy using an innovative mobile ring vaccination trial design based on a ring vaccination strategy responsible for eradicating smallpox that reached areas of new outbreaks. Thoughtful and intensive community engagement in each country enabled the critical community partnership and acceptance of the phase II/III in each country. Due to the delayed clinical trial initiation, relative to the epidemiologic peak of the outbreak in the three countries, vaccine interventions may or may not have played a major role in bringing the epidemic under control. Having demonstrated that clinical trials can be performed during a large outbreak, the global research community can now build on the experience to implement trials more rapidly and efficiently in future outbreaks. Incorporating clinical research needs into planning for future health emergencies and understanding what kind of trial designs is needed for reliable results in an epidemic of limited duration should improve global response to future infectious disease outbreaks.
 
 
Gynecologic Oncology
Volume 147, Issue 1, October 2017, Pages 209-210
Racial Differences in Reasons for Lack of HPV Vaccine Initiation in Adolescent Girls in the US, 2015
A Beavis, M Krakow, K Levinson, A Rositch – Gynecologic Oncology, 2017
Objectives: While cervical cancer rates are higher in black compared to white women, HPV vaccine initiation is lower in white teens compared to black teens. We sought to characterize differences in reasons for non-initiation of the HPV vaccine between parents of black and white adolescent females in 2015.

Awareness of HPV Vaccinations and Barriers to Vaccination Administration Among Underserved Women
R Guerra, A Bhalwal, C Ibarra, N Jooya, SC Robazetti… – Gynecologic Oncology, 2017
Objectives: To delineate awareness and knowledge of HPV vaccinations among medically underserved women who attend health fairs and identify barriers to vaccine administration.

Brain, Behavior, and Immunity
Available online 17 September 2017
Positive Mood on the Day of Influenza Vaccination Predicts Vaccine Effectiveness: A Prospective Observational Cohort Study
K Ayling, L Fairclough, P Tighe, I Todd, V Halliday…
Abstract
Influenza vaccination is estimated to only be effective in 17–53% of older adults. Multiple patient behaviors and psychological factors have been shown to act as ‘immune modulators’ sufficient to influence vaccination outcomes. However, the relative importance of such factors is unknown as they have typically been examined in isolation. The objective of the present study was to explore the effects of multiple behavioral (physical activity, nutrition, sleep) and psychological influences (stress, positive mood, negative mood) on the effectiveness of the immune response to influenza vaccination in the elderly. A prospective, diary-based longitudinal observational cohort study was conducted. One hundred and thirty-eight community-dwelling older adults (65–85 years) who received the 2014/15 influenza vaccination completed repeated psycho-behavioral measures over the two weeks prior, and four weeks following influenza vaccination. IgG responses to vaccination were measured via antigen microarray and seroprotection via hemagglutination inhibition assays at 4 and 16 weeks post-vaccination. High pre-vaccination seroprotection levels were observed for H3N2 and B viral strains. Positive mood on the day of vaccination was a significant predictor of H1N1 seroprotection at 16 weeks post-vaccination and IgG responses to vaccination at 4 and 16 weeks post-vaccination, controlling for age and gender. Positive mood across the 6-week observation period was also significantly associated with post-vaccination H1N1 seroprotection and IgG responses to vaccination at 16 weeks post-vaccination, but in regression models the proportion of variance explained was lower than for positive mood on the day of vaccination alone. No other factors were found to significantly predict antibody responses to vaccination. Greater positive mood in older adults, particularly on the day of vaccination, is associated with enhanced responses to vaccination.